Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeoPharma has signed an agreement with the University of South Florida Research Foundation to acquire worldwide patent rights of a diagnostic technology for early stage detection of ovarian cancer using patient urine samples.
Subscribe to our email newsletter
GeoPharma said that the only ovarian cancer diagnostic test is the CA-125 blood test that is approved by the FDA to monitor progression of the disease. For best accuracy, the CA-125 test is done serially or in combination with other physical tests like transvaginal sonography and pelvic examination.
Preliminary clinical studies have been conducted at the University of South Florida and further studies are under progress. GeoPharma said that it will initiate the necessary steps for FDA approval.
Kotha Sekharam, president of GeoPharma, said: “Ovarian cancer diagnostic test with high reliability, ease of use and detection at an early stage could save thousands of women from untimely deaths. Our technology could offer significant help in this direction.”